Prescribing information

 

    

About Interstellar

The Interstellar: Developing Future Leaders programme has been co-created by Novartis and a steering committee of medical experts, to provide education in dermatology and rheumatology, support innovative service delivery and facilitate the sharing of clinical excellence to improve patient outcomes in patients with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA; AS and nr-axSpA).

 

Introducing the Interstellar: Developing Future Leaders programme

The Interstellar: Developing Future Leaders programme consists of three workshop-led meetings that provide an educational and best practice sharing opportunity for experienced and future leaders in the fields of PsO, PsA and axSpA, who will help pave the way to advance research and improve patient care in dermatology and rheumatology.

Members of the Interstellar: Developing Future Leaders programme have the opportunity to meet with dermatology/rheumatology experts to share knowledge and practical information on best practice approaches to disease management and service delivery.

Interstellar Dermatology 2021 meetings timeline

Laying the foundations for a strong future in PsO management


Nurturing clinical and scientific knowledge, and communicating with conviction as a leading healthcare professional

Advancing, interpreting and integrating research in PsO clinical practice


Enabling evidence generation and addressing unmet research needs to improve patient outcomes and service delivery

Leading improvement and innovation in PsO clinical practice


Driving change and service optimisation as a team leader to improve patient outcomes and service delivery

 

Interstellar Rheumatology 2021 meetings timeline

Laying the foundations for a strong future in PsA and axSpA management


Nurturing clinical and scientific knowledge, and communicating with conviction as a leading healthcare professional

Advancing, interpreting and integrating research in PsA and axSpA clinical practice


Enabling evidence generation and addressing unmet research needs to improve patient outcomes and service delivery

Leading improvement and innovation in PsA and axSpA clinical practice


Driving change and service optimisation as a team leader to improve patient outcomes and service delivery

 

UK | February 2021 | 101683
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]